My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

48.38 -0.08 (-0.15%)

Streaming Delayed Price Updated: 11:37 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

39 40 Next >

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients ↗

June 04, 2024

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

Via Benzinga

3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth ↗

June 03, 2024

Explore three reliable dividend growth stocks for June 2024 to expand your investment profits for the second half of the year.

Via InvestorPlace

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet ↗

June 01, 2024

These are the overpriced growth stocks to sell and buy after these names corrected by 20% to 30% in the coming quarters.

Via InvestorPlace

FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗

May 31, 2024

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from...

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

May 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

May 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

VeeCon 2024 Speakers Announced: X CEO Linda Yaccarino, Content Creator Khaby Lame, Gary Vee Among Special Guests To Appear At Festival That Combines Business, Pop Culture, Web3 ↗

May 29, 2024

For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conference that combines elements of business, pop culture

Via Benzinga

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗

May 28, 2024

Via Benzinga

Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit ↗

May 24, 2024

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence.

Via Benzinga

Topics Lawsuit

Why Vaccine Stocks Rallied This Week ↗

May 24, 2024

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

Via The Motley Fool

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom ↗

May 23, 2024

These are the biotech stocks to buy for a massive rally in the coming quarters on the back of positive clinical progress.

Via InvestorPlace

First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential ↗

May 22, 2024

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.

Via Benzinga

Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M ↗

May 22, 2024

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the health risks of their blood thinner Plavix. The ruling follows a previous...

Via Benzinga

3 Biotech Stocks to Buy Now: May 2024 ↗

May 22, 2024

As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.

Via InvestorPlace

3 Things You Need to Know If You Buy Novavax Today ↗

May 22, 2024

The vaccine maker's recovery story is looking brighter.

Via The Motley Fool

ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development ↗

May 21, 2024

Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma...

Via Benzinga

Topics Artificial Intelligence

Roaring Kitty’s Rally Cry: 3 Meme Stocks to Pounce On Now ↗

May 20, 2024

Jump into action with NVAX, HOOD and WKHS as top meme stocks to buy, offering the chance to capitalize on short squeezes and momentum.

Via InvestorPlace

This Stock Just More Than Doubled in 1 Day: Is It a Buy? ↗

May 19, 2024

The biotech still hasn't lost momentum.

Via The Motley Fool

Could Novavax Become the Next Moderna? ↗

May 17, 2024

Sanofi believes in Novavax's vaccine strengths...

Via The Motley Fool

Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗

May 16, 2024

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...

Via Benzinga

Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement ↗

May 15, 2024

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas.

Via Benzinga

Is DoubleVerify’s 39% Haircut a Buying Opportunity?

May 15, 2024

Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings

Via MarketBeat

Topics Artificial Intelligence Fraud Malware

3 Stocks Under $2 That Can Trade in Double Digits by 2025 ↗

May 15, 2024

These stocks under $2 are likely to surge higher as they represent companies with impending growth catalysts.

Via InvestorPlace

Novavax Stock Just Tripled. Is It Too Late to Buy? ↗

May 15, 2024

Novavax shares have soared and plummeted in recent years.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 14, 2024

Via Benzinga

3 Cheap Biotech Stocks to Buy Now: May 2024 ↗

May 14, 2024

Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.

Via InvestorPlace

3 Meme Stocks That Are Likely to Crater in 2024 ↗

May 14, 2024

These are the meme stocks to avoid as they represent fundamentally weak companies with a sluggish growth outlook.

Via InvestorPlace

Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector ↗

May 13, 2024

Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

May 13, 2024

It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Via InvestorPlace

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.